Jak-Inhibitors Beyond The Label: Emerging Applications In Dermatology

Oral Janus kinase (JAK) inhibitors, including abrocitinib, upadacitinib, baricitinib, and ritlecitinib, are being used off-label in dermatology for a variety of inflammatory skin disorders beyond their approved uses for atopic dermatitis and alopecia areata. A review of 136 articles involving 204 patients found these inhibitors to be effective and generally well-tolerated, with mild adverse events in a minority of cases. Baricitinib, in particular, has shown promise in treating autoimmune and inflammatory skin diseases, such as autoimmune bullous diseases, lupus-related dermatoses, and vitiligo, often achieving rapid symptom control and sustained remission. The findings suggest that JAK inhibitors have significant therapeutic potential in dermatology, offering new treatment options for conditions that lack standardized therapies.